Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
Maria Mirabelli,Eusebio Chiefari,Vera Tocci,Patrizia Caroleo,Stefania Giuliano,Emanuela Greco,Raúl M. Luque,Luigi Puccio,Daniela Foti,Antonio Aversa,Antonio Brunetti +10 more
TLDR
In this article, the authors evaluated the 18-month safety and effectiveness of Dulaglutide (DU) 1.5 mg/once weekly as an add-on to MET or MET plus conventional insulin secretagogues in a study cohort with excess body weight and type 2 diabetes.Abstract:
Aims and methods: The aim of this monocentric retrospective observational study was to evaluate the 18-month safety and effectiveness of GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) 1.5 mg/once weekly as an add-on to metformin (MET) or MET plus conventional insulin secretagogues in a study cohort with excess body weight and type 2 diabetes (T2D). Comparative efficacy versus liraglutide (LIRA) 1.2–1.8 mg/once daily in a study sample naive to GLP-1 RAs, frequency matching for age, gender, T2D duration, degree of glycemic impairment, cardiovascular comorbidities, and medications, was addressed as a secondary aim. Clinical and biochemical data for efficacy outcomes and information on drug discontinuation due to adverse events (AEs) were collected from digital records. Results: Initial analysis included 126 overweight and obese T2D patients (48.4% females). Out of these, 13 discontinued DU due to moderate–severe gastrointestinal AEs after a mean follow-up of 6 (4 standard deviations (SD)) months, while 65 completed 18 months of continuous therapy. At 6 months, there was a significant mean HbA1c reduction of −0.85% (1.17 SD) with respect to baseline values (p < 0.001), which remained stable during 18 months follow-up. These results were accompanied by a moderate weight loss sustained over time, with a mean reduction of −2.0% (4.3 SD) at 6 months and −1.3% (4.8 SD) at 18 months (p = 0.091). At univariate analysis, a negative correlation between baseline body mass index (BMI) and risk of drug discontinuation due to gastrointestinal AEs was observed. The protective effect of obesity against drug discontinuation was confirmed by logistic regression analysis. Neither gender, nor age, nor T2D duration, nor concomitant conventional insulin secretagogue use, nor switching to DU from other GLP-1 RAs influenced its long-term effectiveness. However, higher baseline HbA1c values emerged as predictors of clinically relevant efficacy outcomes, either in terms of HbA1c reduction ≥ 0.5% or body weight loss ≥ 5%. The efficacy outcomes were corroborated by head-to-head comparison with LIRA, a GLP-1 RA with durable beneficial effects on glycemic control and body weight in real-world experiences. With the advantage of once-weekly administration, at 18-month follow-up, a significantly larger fraction of patients on DU therapy reached glycemic targets (HbA1c ≤ 7.0%) when compared to those on LIRA: from 14.8% at baseline (both groups) to 64.8% with DU and 42.6% with LIRA (p = 0.033). Conclusions: Although limited by a retrospective design and lack of constant up-titration for LIRA to the highest dose, these findings indicate that the beneficial responses to DU on a background of MET or MET plus insulin secretagogues are durable, especially in the presence of obesity and greater HbA1c impairment.read more
Citations
More filters
Journal ArticleDOI
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao,Minghe Wang,Zhitong Wen,Zhihong Lu,Lijuan Cui,Chao Fu,Huan Xue,Yunfeng Liu,Yi Zhang +8 more
TL;DR: In this paper, the authors reviewed the therapeutic effects and possible mechanisms of action of GLP-1RAs in the nervous, cardiovascular, and endocrine systems and their correlation with metabolism, tumours and other diseases.
Journal ArticleDOI
Insulin Resistance and Cancer: In Search for a Causal Link.
Eusebio Chiefari,Maria Mirabelli,Sandro La Vignera,Sinan Tanyolaç,Daniela Foti,Antonio Aversa,Antonio Brunetti +6 more
TL;DR: In this paper, the authors provide a concise overview of the most recent literature in this field and discuss how different but interrelated molecular pathways may impact on tumor development, whereas potential chemopreventive properties have been attributed to some commonly used antidiabetic medications.
Journal ArticleDOI
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.
Emilie H. Zobel,Rasmus S. Ripa,Bernt Johan von Scholten,Bernt Johan von Scholten,Viktor Rotbain Curovic,Andreas Kjaer,Tine W. Hansen,Peter Rossing,Peter Rossing,Joachim Størling,Joachim Størling +10 more
TL;DR: In this paper, the anti-inflammatory effects of glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment in T2D patients were investigated.
Journal ArticleDOI
Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms.
TL;DR: In this article, the clinical and experimental impacts of various classes of antidiabetic drugs on the circulating levels of oxLDL were reviewed and a multitude of mechanisms were explored to counter the undesirable effects of oxidized low-density lipoprotein in macrophages, endothelial cells, and vascular smooth muscle cells.
Journal ArticleDOI
The Hormetic Effect of Metformin: “Less Is More”?
TL;DR: In this paper, the effects of MTF on T2DM on the principal target organs, such as liver, gut, adipose tissue, endothelium, heart, and skeletal muscle, were described.
References
More filters
Journal ArticleDOI
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P. Marso,Stephen C. Bain,A. Consoli,Freddy G. Eliaschewitz,Esteban Jódar,Lawrence A. Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,O Hansen,Anders G. Holst,Jonas Pettersson,Tina Vilsbøll +14 more
TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.
Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
TL;DR: Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.
Journal ArticleDOI
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing,Wei Lang,Thomas A. Wadden,Monika M. Safford,William C. Knowler,Alain G. Bertoni,James O. Hill,Frederick L. Brancati,Anne L. Peters,Lynne E. Wagenknecht +9 more
TL;DR: Modest weight losses of 5 to <10% were associated with significant improvements in CVD risk factors at 1 year, but larger weight losses had greater benefits.
Journal ArticleDOI
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F.E. Mann,David D. Ørsted,Kirstine Brown-Frandsen,Steven P. Marso,Neil Poulter,Søren Rasmussen,Karen Tornøe,Bernard Zinman,John B. Buse +8 more
TL;DR: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo.
Journal ArticleDOI
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Rohan Khera,Mohammad Hassan Murad,Apoorva K. Chandar,Parambir S. Dulai,Zhen Wang,Larry J. Prokop,Rohit Loomba,Michael Camilleri,Siddharth Singh +8 more
TL;DR: All active agents were associated with significant excess weight loss compared with placebo at 1 year and phentermine-topiramate, naltrexone-bupropion, and liraglutide, each associated with 5% weight loss at 52 weeks, were linked with the highest odds of adverse event-related treatment discontinuation.